-
Notifications
You must be signed in to change notification settings - Fork 0
Commit
This commit does not belong to any branch on this repository, and may belong to a fork outside of the repository.
- Loading branch information
Showing
11 changed files
with
190 additions
and
12 deletions.
There are no files selected for viewing
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| Original file line number | Diff line number | Diff line change |
|---|---|---|
| @@ -1,3 +1,3 @@ | ||
| [IG] | ||
| ig = fsh-generated/resources/ImplementationGuide-cll-guideline.medizin.uni-greifswald.de.json | ||
| ig = fsh-generated/resources/ImplementationGuide-de.uni-greifswald.medizin.cll-guideline.json | ||
| template = de.netzwerk-universitaetsmedizin.codexplus.celida.template#0.1.0 |
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
33 changes: 33 additions & 0 deletions
33
input/fsh/CLL-QI/recommendation-CLL-QI-4/Intervention-a.fsh
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| Original file line number | Diff line number | Diff line change |
|---|---|---|
| @@ -0,0 +1,33 @@ | ||
| /************************/ | ||
| /* Intervention Plans */ | ||
| /************************/ | ||
| Instance: QIRezidivKlinischeStudien | ||
| InstanceOf: recommendation-plan | ||
| Usage: #definition | ||
| Title: "QI 4: Einschluss von CLL-Pat. mit Rezidiv in klinische Studien (modifiziert 2024))" | ||
| Description: "Patient*innen mit einem Rezidiv sollen, sofern eine passende klinische Studie verfügbar ist, die Therapie im Rahmen einer klinischen Studie angeboten werden.)" | ||
| * insert publisher-experimental-version | ||
| * name = "QIRezidivKlinischeStudien" | ||
| * title = "QI 4: Einschluss von CLL-Pat. mit Rezidiv in klinische Studien (modifiziert 2024)" | ||
| * description = "Patient*innen mit einem Rezidiv sollen, sofern eine passende klinische Studie verfügbar ist, die Therapie im Rahmen einer klinischen Studie angeboten werden." | ||
| * date = "2024-07" | ||
| * status = #active | ||
| * insert rs-combination-all | ||
| * subjectCanonical = Canonical(PopulationQIRezidivKlinischeStudien) | ||
| * extension[partOf].valueCanonical = Canonical(RecCollectionQIRezidivKlinischeStudien) | ||
| * action[assessment][+] | ||
| * definitionCanonical = Canonical(CLLPatientInCLLRelapseStudy) | ||
|
|
||
| /**********************/ | ||
| /* Recommended Actions */ | ||
| /**********************/ | ||
| Instance: CLLPatientInCLLRelapseStudy | ||
| InstanceOf: ActivityDefinition | ||
| Usage: #definition | ||
| Title: "CLLPatientInCLLRelapseStudy" | ||
| Description: "CLLPatientInCLLRelapseStudy" | ||
| * name = "CLLPatientInCLLRelapseStudy" | ||
| * insert publisher-experimental-version | ||
| * status = #active | ||
| * description = "Patient*innen mit einem Rezidiv sollen, sofern eine passende klinische Studie verfügbar ist, die Therapie im Rahmen einer klinischen Studie angeboten werden." | ||
| * code = $cs-cll#cllrlpsincl "Inclusion into specific CLL relapse treatment study" |
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| Original file line number | Diff line number | Diff line change |
|---|---|---|
| @@ -0,0 +1,22 @@ | ||
| /**************/ | ||
| /* Population */ | ||
| /**************/ | ||
| Instance: PopulationQIRezidivKlinischeStudien | ||
| InstanceOf: recommendation-eligibility-criteria | ||
| Usage: #definition | ||
| Title: "Population CLL Rezidiv einschluss in klinische Studien" | ||
| Description: "Population CLL Pat. mit Rezidiv" | ||
| * status = #active | ||
| * actual = false | ||
| * name = "PopulationQIRezidivKlinischeStudien" | ||
| * description = "QI 4: Einschluss von Pat. mit Rezidiv in klinische Studien (modifiziert 2024)" | ||
| * characteristic[0].definitionByCombination | ||
| * code = #all-of | ||
| * characteristic[condition][+] | ||
| //* linkId = "CLL" | ||
| * definitionByTypeAndValue | ||
| * type = $sct#404684003 "Clinical finding (finding)" | ||
| * valueCodeableConcept = $sct#92814006 "Chronic lymphoid leukaemia, disease" | ||
| * characteristic[condition][+] | ||
| * definitionByTypeAndValue | ||
| * valueCodeableConcept = $cs-cll#cllrlpstherapy "CLL-relapse under treatment" |
22 changes: 22 additions & 0 deletions
22
input/fsh/CLL-QI/recommendation-CLL-QI-4/recommendation.fsh
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| Original file line number | Diff line number | Diff line change |
|---|---|---|
| @@ -0,0 +1,22 @@ | ||
| /**********************************/ | ||
| /* Recommendation CLL-QI 4 */ | ||
| /**********************************/ | ||
| /* Recommendation Collection Plan */ | ||
| /**********************************/ | ||
| Instance: RecCollectionQIRezidivKlinischeStudien | ||
| InstanceOf: recommendation | ||
| Usage: #definition | ||
| Title: "QI 4: Einschluss von CLL-Pat. mit Rezidiv in klinische Studien (modifiziert 2024)" | ||
| Description: "Patient*innen mit einem Rezidiv sollen, sofern eine passende klinische Studie verfügbar ist, die Therapie im Rahmen einer klinischen Studie angeboten werden." | ||
| * name = "RecommendationCollection_QI_4" | ||
| * title = "QI 4: Einschluss von CLL-Pat. mit Rezidiv in klinische Studien (modifiziert 2024)" | ||
| * date = "2024-07-08" | ||
| * status = #active | ||
| * description = "Patient*innen mit einem Rezidiv sollen, sofern eine passende klinische Studie verfügbar ist, die Therapie im Rahmen einer klinischen Studie angeboten werden." | ||
| * insert publisher-experimental-version | ||
| * insert rs-combination-all | ||
| * action[+] | ||
| * title = "QIRezidivKlinischeStudien" | ||
| * code = $cs-common-process#guideline-based-care | ||
| * description = "QI 4: Einschluss von CLL-Pat. mit Rezidiv in klinische Studien (modifiziert 2024)" | ||
| * definitionCanonical = Canonical(QIRezidivKlinischeStudien) |
54 changes: 54 additions & 0 deletions
54
input/fsh/CLL-QI/recommendation-CLL-QI-5/Intervention-a.fsh
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| Original file line number | Diff line number | Diff line change |
|---|---|---|
| @@ -0,0 +1,54 @@ | ||
| /************************/ | ||
| /* Intervention Plans */ | ||
| /************************/ | ||
| Instance: QICLLErstlinienTherapie | ||
| InstanceOf: recommendation-plan | ||
| Usage: #definition | ||
| Title: "QI 5: Bcl-2- oder BTK-Inhibitor-basierten Therapie als Erstlinientherapie (neu 2024)" | ||
| Description: "Patient*innen mit CLL sollen in der Erstlinienbehandlung mit einer Bcl-2- oder BTK-Inhibitor-basierten Therapie behandelt werden." | ||
| * insert publisher-experimental-version | ||
| * name = "QICLLErstlinienTherapie" | ||
| * title = "QI 5: Bcl-2- oder BTK-Inhibitor-basierten Therapie als Erstlinientherapie (neu 2024)" | ||
| * description = "Patient*innen mit CLL sollen in der Erstlinienbehandlung mit einer Bcl-2- oder BTK-Inhibitor-basierten Therapie behandelt werden." | ||
| * date = "2024-07" | ||
| * status = #active | ||
| * subjectCanonical = Canonical(PopulationQIMedikationErstlinienTherapie) | ||
| * extension[partOf].valueCanonical = Canonical(RecCollectionQIMedikationErstlinienTherapie) | ||
| * insert rs-combination-exactly(1) | ||
| * action[drugAdministration][+] | ||
| * definitionCanonical = Canonical(ErstlinieMitBCL2beiCLL) | ||
| * code = $sct#432102000 "Administration of substance (procedure)" | ||
| * action[drugAdministration][+] | ||
| * definitionCanonical = Canonical(ErstlinieMitBTKbeiCLL) | ||
| * code = $sct#432102000 "Administration of substance (procedure)" | ||
|
|
||
| /**********************/ | ||
| /* Recommended Actions */ | ||
| /**********************/ | ||
| /* | ||
| Instance: ErstlinieMitBCL2beiCLLQI // TODO ich habe die selbe Instance bereits für das CLL Empfehlungsprojekt definiert, damit die von einander unabhängig sein können, habe ich diese aber anders genannt, so ist auch SUSHI zufrieden, dass ich nicht die selbe Instance zweimal habe. | ||
| InstanceOf: drug-administration-action | ||
| Usage: #definition | ||
| Title: "Erstlinienterapie mit BCL2-Inhibitor bei CLL" | ||
| Description: "Erstlinienterapie mit BCL2-Inhibitor bei CLL" | ||
| * name = "ErstlinieMitBCL2beiCLL" | ||
| * insert publisher-experimental-version | ||
| * status = #active | ||
| * description = "Erstlinienterapie mit BCL2-Inhibitor bei CLL" | ||
| * code = $sct#432102000 "Administration of substance (procedure)" | ||
| * productCodeableConcept | ||
| * coding[sct] = $sct#725567006 "B-cell lymphoma 2 inhibitor" | ||
| Instance: ErstlinieMitBTKbeiCLLQI // TODO ich habe die selbe Instance bereits für das CLL Empfehlungsprojekt definiert, damit die von einander unabhängig sein können, habe ich diese aber anders genannt, so ist auch SUSHI zufrieden, dass ich nicht die selbe Instance zweimal habe. | ||
| InstanceOf: drug-administration-action | ||
| Usage: #definition | ||
| Title: "Rezidivtherapie mit BTK-Inhibitor bei CLL" | ||
| Description: "Rezidivtherapie mit BTK-Inhibitor bei CLL" | ||
| * name = "RezidivtherapieMitBTKbeiCLL" | ||
| * insert publisher-experimental-version | ||
| * status = #active | ||
| * description = "Rezidivtherapie mit BTK-Inhibitor bei CLL" | ||
| * code = $sct#432102000 "Administration of substance (procedure)" | ||
| * productCodeableConcept | ||
| * coding[sct] = $sct#710227007 "Non-specific protein-tyrosine kinase inhibitor" | ||
| */ |
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| Original file line number | Diff line number | Diff line change |
|---|---|---|
| @@ -0,0 +1,20 @@ | ||
|
|
||
| Instance: PopulationQIMedikationErstlinienTherapie | ||
| InstanceOf: recommendation-eligibility-criteria | ||
| Usage: #definition | ||
| Title: "Population für CLL Erstlinien-Therapie" | ||
| Description: "Patient*innen mit CLL sollen in der Erstlinienbehandlung mit einer Bcl-2- oder BTK-Inhibitor-basierten Therapie behandelt werden." | ||
| * status = #active | ||
| * actual = false | ||
| * name = "PopulationQIMedikationErstlinienTherapie" | ||
| * description = "Patient*innen mit CLL sollen in der Erstlinienbehandlung mit einer Bcl-2- oder BTK-Inhibitor-basierten Therapie behandelt werden." | ||
| * characteristic[0].definitionByCombination | ||
| * code = #all-of | ||
| * characteristic[condition][+] | ||
| //* linkId = "CLL" | ||
| * definitionByTypeAndValue | ||
| * type = $sct#404684003 "Clinical finding (finding)" | ||
| * valueCodeableConcept = $sct#92814006 "Chronic lymphoid leukaemia, disease" | ||
| * characteristic[condition][+] | ||
| * definitionByTypeAndValue | ||
| * valueCodeableConcept = $cs-cll#cllflt "CLL-specific firstline treatment" |
24 changes: 24 additions & 0 deletions
24
input/fsh/CLL-QI/recommendation-CLL-QI-5/recommendation.fsh
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| Original file line number | Diff line number | Diff line change |
|---|---|---|
| @@ -0,0 +1,24 @@ | ||
| /**********************************/ | ||
| /* Recommendation CLL-QI 5 */ | ||
| /**********************************/ | ||
| /* Recommendation Collection Plan */ | ||
| /**********************************/ | ||
| Instance: RecCollectionQIMedikationErstlinienTherapie | ||
| InstanceOf: recommendation | ||
| Usage: #definition | ||
| Title: "QI 5: Bcl-2- oder BTK-Inhibitor-basierten Therapie als Erstlinientherapie (neu 2024)" | ||
| Description: "Patient*innen mit CLL sollen in der Erstlinienbehandlung mit einer Bcl-2- oder BTK-Inhibitor-basierten Therapie behandelt werden." | ||
| * name = "RecommendationCollection_QI_5" | ||
| * title = "QI 5: Bcl-2- oder BTK-Inhibitor-basierten Therapie als Erstlinientherapie (neu 2024)" | ||
| * date = "2024-07-08" | ||
| * status = #active | ||
| * description = "Patient*innen mit CLL sollen in der Erstlinienbehandlung mit einer Bcl-2- oder BTK-Inhibitor-basierten Therapie behandelt werden." | ||
| * insert publisher-experimental-version | ||
| * insert rs-combination-all | ||
| * action[+] | ||
| * title = "QICLLErstlinienTherapie" | ||
| * code = $cs-common-process#guideline-based-care | ||
| * description = "QI 5: Bcl-2- oder BTK-Inhibitor-basierten Therapie als Erstlinientherapie (neu 2024)" | ||
| * definitionCanonical = Canonical(QICLLErstlinienTherapie) | ||
|
|
||
|
|
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters